Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-74
SponsorHuazhong University of Science and Technology

About this trial

To further explore the application prospects of integrated Traditional Chinese and Western medicine in chronic disease prevention and control and health management, this study intends to establish a large, prospective, integrated Traditional Chinese and Western medicine cohort in Hubei Province. This study will conduct long-term follow-up and multi-dimensional data collection to systematically reveal the associations between Traditional Chinese Medicine (TCM) constitution types and chronic diseases, the aging process, and multi-morbidity, thereby developing an integrated health management strategy with local characteristics. This study will fill the current gap in systematic evidence linking TCM constitutions to the prevalence of modern diseases, providing a solid demographic and biological foundation for the integrated development of Traditional Chinese and Western medicine. It will also contribute to meeting the needs for early disease warning, early intervention, and personalized care under the "Healthy China" strategic goal.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Targeting urban and rural residents across multiple regions in Hubei Province, this study plans to recruit 1 million participants. Standardized protocols will be employed for baseline questionnaire surveys, physical examinations, and biological sample collection.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China

Time frame
From enrollment to the 10-year follow-up
2

Incidence of major chronic diseases (coronary heart disease, stroke, diabetes, COPD, lung cancer, colorectal cancer, gastric cancer, liver cancer, and esophageal cancer)

Time frame
From baseline (enrollment) to 10-year follow-up Measurement Tool: Standardized physician-adjudicated diagnosis based on ICD-10 codes, confirmed through hospital electronic medical records and disease registries

Secondary outcomes

1

All-cause mortality

Time Frame: From baseline to 10-year follow-up Measurement Tool: Death registry linkage and hospital records Unit of Measure: Mortality rate per 1,000 person-years

Time frame
From baseline to 10-year follow-up

Other outcomes

1

Cause-specific mortality (cardiovascular, cancer, respiratory, metabolic)

Time Frame: From baseline to 10-year follow-up Measurement Tool: Death registry and ICD-10 coded cause of death Unit of Measure: Mortality rate per 1,000 person-years

Time frame
From baseline to 10-year follow-up
2

Prevalence and progression of multimorbidity (≥2 chronic conditions)

Time Frame: Baseline to 10-year follow-up Measurement Tool: Questionnaire survey and physician-adjudicated diagnosis using ICD-10 Unit of Measure: % of participants with multimorbidity

Time frame
Baseline to 10-year follow-up

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Huazhong University of Science and Technology

Lead sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborator

Hubei College of Traditional Chinese Medicine

Collaborator

Hubei Hospital of Traditional Chinese Medicine

Collaborator

Hubei Provincial Center for Disease Control and Prevention

Collaborator

Wuhan Center for Disease Control and Prevention

Collaborator

This trial is not recruiting at the moment. You can still explore other options: